Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | NKTR-255 |
Trade Name | |
Synonyms | NKTR255|NKTR 255 |
Drug Descriptions |
NKTR-255 comprises polymer-conjugated human IL-15, which binds to the IL-15 receptor and acts as an agonist, potentially resulting in enhanced anti-tumor immune response in combination with antibody therapies (Cancer Res July 1 2019 (79) (13 Supplement) 3265). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C165666 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Avelumab + NKTR-255 | Avelumab NKTR-255 | 0 | 1 |
Cetuximab + NKTR-255 | Cetuximab NKTR-255 | 0 | 1 |
Daratumumab + NKTR-255 | Daratumumab NKTR-255 | 0 | 1 |
Durvalumab + NKTR-255 | Durvalumab NKTR-255 | 0 | 1 |
NKTR-255 | NKTR-255 | 0 | 4 |